A specialty pharmaceutical company sought to address a critical commercialization challenge for a therapy used in nephrology. Although the product had broad payer coverage, many healthcare professionals (HCPs) underestimated patient access, creating an unnecessary barrier to prescribing.
The challenge was not the availability of coverage itself, but the gap between actual formulary access and physician perception. In a therapeutic area where confidence in reimbursement can significantly influence treatment decisions, uncertainty around coverage was discouraging physicians from prescribing the therapy for appropriate patients.
As part of Indegene’s precision HCP engagement capabilities, BioPharm Communications, an Indegene Company, designed and implemented a targeted engagement strategy to align physician perceptions with real-world access and translate existing payer coverage into measurable prescription growth.

Rather than promoting the therapy broadly, the program addressed a specific commercial barrier by helping physicians reconcile perceived access limitations with the reality of available coverage.
The program engaged more than half of the targeted HCP audience, generating 2,794 engagements from approximately 5,000 providers across digital and print channels.
By delivering localized formulary information tailored to each physician’s prescribing environment, the program helped improve confidence in patient access and drove a measurable 3.9% increase in prescribing behavior. It also delivered a 4:1 return on investment, showing how correcting access misperceptions can unlock greater value from existing payer coverage.
3.9%↑
increase in prescribing behavior
4:1
return on investment
50%+
HCP engagement